Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.32 |
| ▸ | UBE2D3 | P61077 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5682286 | 0.93 | NPC1 (0.32) | NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL5680337 | 0.83 | — | — | |
| SCHEMBL5707623 | 0.75 | NPC1 (0.31) | NPC1HTTRAB9AALDH1A1 | |
| SCHEMBL5707590 | 0.75 | NPC1 (0.33) | NPC1HTTRAB9AL3MBTL1MAPT | |
| SCHEMBL5677512 | 0.72 | SLC6A2 (0.31) | HTTMAPT | |
| SCHEMBL5679573 | 0.72 | SLC6A2 (0.31) | HTTMAPT | |
| SCHEMBL5677693 | 0.72 | SLC6A2 (0.31) | HTTMAPT | |
| SCHEMBL30751007 | 0.71 | SLC6A2 (0.32) | NPC1HTTRAB9APOLBALDH1A1 | |
| SCHEMBL5707551 | 0.70 | NPC1 (0.32) | NPC1HTTRAB9AMAPTPOLB | |
| Hydrochloric Acid SCHEMBL29878392 | 0.70 | SLC6A2 (0.32) | HTTMAPTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1631573-A1 | PROCESS FOR THE PREPARATION OF RIBOFURANOSE DERIVATIVES | INALCO SpA (IT) | 2006-03-08 | — | — | EP | claimed |
| US-6891036-B2 | Process for the preparation of ribofuranose derivatives | INALCO S.P.A. (IT) | 2005-05-10 | — | — | US | claimed |
| WO-2004069851-A1 | PROCESS FOR THE PREPARATION OF RIBOFURANOSE DERIVATIVES | INALCO S.P.A. (IT) | 2004-08-19 | — | — | WO | claimed |
| US-20040158059-A1 | Process for the preparation of ribofuranose derivatives | INALCO S.P.A. (IT) | 2004-08-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158059-A1 | Process for the preparation of ribofuranose derivatives | RNGTT, RPIA, MRM1 | MGLL 3426/4885UTS2R 3517/4885UBE2D3 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.